Arbutus to Present at Jefferies London Healthcare Conference
Arbutus Biopharma (Nasdaq: ABUS), a clinical-stage biopharmaceutical company focused on developing a functional cure for chronic hepatitis B virus (cHBV) infection, has announced its participation in the Jefferies London Healthcare Conference. The company will conduct a fireside chat on November 21, 2024 at 12:00 pm GMT / 7:00 am EST. Investors can access the live webcast through the company's investor relations website, with an archived replay available for a time after the event.
Arbutus Biopharma (Nasdaq: ABUS), un'azienda biofarmaceutica in fase clinica focalizzata sullo sviluppo di una cura funzionale per l'infezione cronica da virus dell'epatite B (cHBV), ha annunciato la sua partecipazione alla Jefferies London Healthcare Conference. L'azienda condurrà una chat informale il 21 novembre 2024 alle 12:00 GMT / 7:00 EST. Gli investitori possono accedere alla diretta streaming tramite il sito web delle relazioni con gli investitori dell'azienda, con una registrazione disponibile per un periodo dopo l'evento.
Arbutus Biopharma (Nasdaq: ABUS), una empresa biofarmacéutica en etapa clínica centrada en desarrollar una cura funcional para la infección crónica por el virus de la hepatitis B (cHBV), ha anunciado su participación en la Jefferies London Healthcare Conference. La empresa llevará a cabo una charla informal el 21 de noviembre de 2024 a las 12:00 pm GMT / 7:00 am EST. Los inversores pueden acceder a la transmisión en vivo a través del sitio web de relaciones con inversores de la empresa, con una repetición archivada disponible por un tiempo después del evento.
Arbutus Biopharma (Nasdaq: ABUS)는 만성 B형 간염 바이러스(cHBV) 감염에 대한 기능적 치료법 개발에 집중하는 임상 단계의 생명공학 회사로, Jefferies London Healthcare Conference에 참여한다고 발표했습니다. 이 회사는 2024년 11월 21일 오후 12시 GMT / 오전 7시 EST에 간담회를 진행할 예정입니다. 투자자들은 회사의 투자자 관계 웹사이트를 통해 실시간 웹캐스트에 접속할 수 있으며, 이벤트 후 일정 기간 동안 아카이브 재방송도 제공될 예정입니다.
Arbutus Biopharma (Nasdaq: ABUS), une entreprise biopharmaceutique en phase clinique axée sur le développement d'un traitement fonctionnel pour l'infection chronique par le virus de l'hépatite B (cHBV), a annoncé sa participation à la Jefferies London Healthcare Conference. L'entreprise réalisera une discussion informelle le 21 novembre 2024 à 12h00 GMT / 7h00 EST. Les investisseurs peuvent accéder à la diffusion en direct via le site web des relations avec les investisseurs de l'entreprise, avec une rediffusion archivée disponible pendant un certain temps après l'événement.
Arbutus Biopharma (Nasdaq: ABUS), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf die Entwicklung einer funktionalen Heilung für chronische Hepatitis-B-Virus(cHBV)-Infektionen konzentriert, hat seine Teilnahme an der Jefferies London Healthcare Conference angekündigt. Das Unternehmen wird am 21. November 2024 um 12:00 Uhr GMT / 7:00 Uhr EST ein Gespräch führen. Investoren können über die Website der Investor Relations des Unternehmens an dem Live-Webcast teilnehmen, und eine aufgezeichnete Wiederholung wird nach der Veranstaltung für einige Zeit zur Verfügung stehen.
- None.
- None.
WARMINSTER, Pa., Nov. 14, 2024 (GLOBE NEWSWIRE) -- Arbutus Biopharma Corporation (Nasdaq: ABUS), (“Arbutus” or the “Company”), a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop a functional cure for people with chronic hepatitis B virus (cHBV) infection, today announced that the Company will present at and host one-on-one meetings at the following upcoming investor conference:
Jefferies London Healthcare Conference: Fireside Chat on November 21, 2024 at 12:00 pm GMT / 7:00 am EST
To access the live webcast of the fireside chat, please visit: https://investor.arbutusbio.com/events-presentations. An archived replay of the webcast will be available on the Arbutus website for a limited time after the event.
About Arbutus
Arbutus Biopharma Corporation (Nasdaq: ABUS) is a clinical-stage biopharmaceutical company leveraging its extensive virology expertise to develop novel therapeutics with distinct mechanisms of action, which can potentially be combined to provide a functional cure for patients with chronic hepatitis B virus (cHBV). We believe the key to success in developing a functional cure involves suppressing HBV DNA, reducing surface antigen, and boosting HBV-specific immune responses. Our pipeline of internally developed, proprietary compounds includes an RNAi therapeutic, imdusiran (AB-729), and an oral PD-L1 inhibitor, AB-101. Imdusiran has generated meaningful clinical data demonstrating an impact on both surface antigen reduction and reawakening of the HBV-specific immune response. Imdusiran is currently in two Phase 2a combination clinical trials. AB-101 is currently being evaluated in a Phase 1a/1b clinical trial. For more information, visit www.arbutusbio.com.
Contact Information
Investors and Media
Lisa M. Caperelli
Vice President, Investor Relations
Phone: 215-206-1822
Email: lcaperelli@arbutusbio.com
FAQ
When is Arbutus Biopharma (ABUS) presenting at the Jefferies London Healthcare Conference 2024?
How can investors watch Arbutus Biopharma's (ABUS) Jefferies Conference presentation?
What is the main focus of Arbutus Biopharma's (ABUS) research?
